How Can We Help?
Skip to content
AAALAC Accredited In Vivo Animal ADME Studies

Tissue Dissection Studies to Evaluate In Vivo Distribution

A sponsor may elect to add a Tissue Dissection study to determine tissue concentration of radiolabeled drug in a nonclinical in vivo ADME study when distribution data is needed for a specific tissue or organ.

Our Approach to Tissue Dissection to Assess Localized Drug Concentration

Tissue Dissection is one of our specialized in vivo ADME studies performed by our sister lab in Tokai, Japan. This study can tell a drug developer the drug concentration in tissues and organs, as part of a distribution study in the relevat animal model.

The Drug Development Solutions Center has accumulated over 50 years’ experience performing radioisotope (RI) experimentation, synthesis, and purity checks for pharmaceutical companies as the leading in vivo ADME CRO in Japan. The facilities are AAALAC-accredited to meet compliance with ethical requirements upheld by FDA, EMA, and PMDA for all animal studies– find out more about the Drug Development Solutions Center’s radiolabeled compound synthesis and in vivo ADME capabilities.

In vivo time-course distribution of a drug and its metabolites in various tissues can be determined by quantifying radiolabeled drug in dissected target tissues from treated animals of a clinically relevant species at several time points, out to complete excretion.

tissue dissection is part of in vivo adme distribution studies using radiolabeled compound to find drug concentration in tissues and organs

Persistency and plasma protein binding ratio are also analyzed to complement drug concentration data. In the case of considerable persistence of tissue radioactivity, the chemical form of residual radioactivity is analyzed.

Tissue Dissection Study Capabilities

HUMAN CYP MARKERSUGT, MAO AND OTHERSANIMAL P450SDRUG TRANSPORTTissue Options
1′ -Hydroxy midazolam (3A4)
6β-Hydroxy testosterone (3A4)
Oxidized nifedipine (3A4)
ortho-Hydroxy atorvastatin (3A4)
Acetaminophen (1A2)
Dextrorphan (2D6)
Hydroxy bufuralol (2D6)
7-Hydroxy coumarin (2A6)
Hydroxy bupropion (2B6)
8-Hydroxy efavirenz (2B6)
6α-Hydroxy paclitaxel (2C8)
N-Desethyl amodiaquine (2C8)
4′ -Hydroxy diclofenac (2C9)
4-Hydroxy tolbutamide (2C9)
4′ -Hydroxy mephenytoin (2C19)
6-Hydroxy chlorzoxazone (2E1)
Hydroxy ebastine (2J2)
12-Hydroxy lauric acid (4A11)
Estradiol-3-β-D- glucuronide (UGT1A1)
Chenodeoxycholic acid glucuronide (UGT1A3)
Trifluoperazine glucuronide (UGT1A4)
Naphthol glucuronide (UGT1A6)
Propofol glucuronide (UGT1A9)
Morphine-3-β-D-glucuronide (UGT2B7)
Testosterone-β-D glucuronide (UGT2B17)
4-Methylumbelliferyl glucuronide (UGTs)
5-Hydroxy tryptophol (MAO-A)
Dimethylamino benzaldehyde (MAO-B)
Vanillic acid (Aldehyde Oxidase)
Phthalazone (Aldehyde Oxidase)
5-Aceominosalicylic acid (NAT-1)
Rat Hydroxy- testosterone (2α, 6β, 7α, 16β)
Dog Hydroxy testosterone
(6β, 16α)
Mouse Hydroxy- testosterone (6β, 15α, 16β)
Monkey Hydroxy-testosterone (2β, 6β, 16α, 16β)
Digoxin (MDR1)
Prazosin (BCRP)
Plasma
Mandibular gland, Fat
Ileum
Blood
Mandibular lymph node
Brown fat
Urinary bladder
Thymus
Skeletal muscle
Testis*
Cerebellum
Heart
Skin
Epididymis*
Pituitary gland
Lung
Bone Marrow
Prostate gland*
Stomach
Uterus*
Pituitary gland
Spleen
Duodenum
Trachea
Pancreas
Colon

*Can be fractionated 
**Only male
***Only female
Other tissue types may be available upon request.

Which Studies & Why

Not sure which in vivo studies you should plan before your drug goes to first in-human (FIH) clinical trials? Read our quick guide outlining regulatory expectations and basic study outlines for each basic in vivo study we offer

Study director analyst in vitro ADME studies

In Vivo ADME Science

Access ADME™ is your go-to repository for our scientists’ content relevant to radiolabeling and in vivo drug development, including information about regulatory expectations and expertise of our Tokai team

Radiolabeled in vivo animal studies to collect ADME data for your drug